Publications

Al-Samkari H, Loren AW, Lee AI. The case for classical haematology: the impact of a name and the future of a field. Lancet Haematol. 2022 Jun;9(6):e455-e459. doi: 10.1016/S2352-3026(22)00096-5. Epub 2022 Apr 29. PMID: 35500590.

Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov. 2022 Nov 2;3(6):554-567. doi: 10.1158/2643-3230.BCD-21-0220. PMID: 35926182; PMCID: PMC9894566.

Biancon G, Busarello E, Joshi P, Lesch BJ, Halene S, Tebaldi T. Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seq. STAR Protoc. 2022 Dec 16;3(4):101823. doi: 10.1016/j.xpro.2022.101823. Epub 2022 Nov 16. PMID:36595959; PMCID: PMC9676202.

VanOudenhove J, Halene S, Mendez L. Is it the time to integrate novel sequencing technologies into clinical practice? Curr Opin Hematol. 2023 Mar 1;30(2):70-77. doi: 10.1097/MOH.0000000000000754. Epub 2022 Dec 30. PMID:36602939.

Fischer MA, Song Y, Arrate MP, Gbyli R, Villaume MT, Smith BN, Childress MA, Stricker TP, Halene S, Savona MR. Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes. Haematologica. 2023 Feb 1;108(2):522-531. doi: 10.3324/haematol.2022.280631. PMID: 35979721; PMCID: PMC9890032.

Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Stahl M, Stein EM, Huntington SF, Zeidan AM. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leuk Lymphoma. 2023 Feb;64(2):454-461. doi: 10.1080/10428194.2022.2140288. Epub 2022 Dec 9. PMID: 36493798; PMCID: PMC9957935.

Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Adv. 2023 Mar 14;7(5):734-743. doi: 10.1182/bloodadvances.2022008259. PMID: 35917456; PMCID: PMC9989521.

Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers (Basel). 2022 May 14;14(10):2434. doi: 10.3390/cancers14102434. PMID: 35626039; PMCID: PMC9140008.

Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia. 2022 May;36(5):1313-1323. doi: 10.1038/s41375-022-01536-x. Epub 2022 Mar 10. PMID: 35273342; PMCID: PMC9103411.

Boddu PC, Gupta AK, Kim JS, Neugebauer KM, Waldman T, Pillai MM. Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase. Commun Biol. 2021 Oct 13;4(1):1184. doi: 10.1038/s42003-021-02690-1. PMID: 34645977; PMCID: PMC8514589.

Bewersdorf JP, Parmar N, Israel GM, Gettinger SN, Lee AI. Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases. J Thromb Thrombolysis. 2021 Oct;52(3):854-862. doi: 10.1007/s11239-021-02428-0. Epub 2021 Mar 25. PMID: 33765243.

Bewersdorf JP, Patel KK, Huntington SF, Zeidan AM. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Adv. 2021 Nov 23;5(22):4686-4690. doi: 10.1182/bloodadvances.2021005472. PMID: 34525174; PMCID: PMC8759135.

Shallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, Podoltsev NA, Ma X. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Ther Adv Hematol. 2021 Nov 30;12:20406207211043404. doi:10.1177/20406207211043404. PMID: 35154624; PMCID: PMC8832334.

Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leuk Lymphoma. 2021 Nov;62(11):2777-2784. doi: 10.1080/10428194.2021.1933477. Epub 2021 Jun 21. PMID: 34151696.

Li P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. Front Oncol. 2021 Sep 13;11:730503. doi: 10.3389/fonc.2021.730503. PMID:34589432; PMCID: PMC8474637.

Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia. 2022 Mar 10. doi: 10.1038/s41375-022-01536-x. Epub ahead of print. PMID: 35273342.

Liu W, Teodorescu P, Halene S, Ghiaur G. The Coming of Age of Preclinical Models of MDS. Front Oncol. 2022 Mar 16;12:815037. doi:10.3389/fonc.2022.815037. PMID: 35372085; PMCID: PMC8966105.